Ascenta spinoff Ascentage Pharma, which also counts 3SBio and Unity Biotechnology as backers, has filed to float having raised about $235m in funding.

Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.

GlaxoSmithKline-backed Principia Biopharma has filed for an $86.3m initial public offering having raised $50m earlier this month.

The AstraZeneca antibacterial medicine spinout aims to raise $86.3m in an initial public offering that could also herald an exit for Novo.

JD.com and Advance Publications both hold stakes greater than 5% in the fashion e-commerce platform, which has raised more than $700m in funding.

Tasly-backed immunotherapy developer I-Mab Biopharma is reportedly eyeing a Hong Kong flotation having recently raised $220m in funding.

The mobile input technology developer plans to float in the US, two years after raising cash in an SIG-backed round.

The Tencent and Xiaomi-backed news aggregation platform was founded two years ago but was reportedly valued at $1.6bn in March.

Sensyne Health has completed a $76m initial public offering and will begin trading on Aim tomorrow, offering an exit to University of Oxford.